ClinicalTrials.gg
Active, not recruitingNCT06284629PD-DigiCareUpdated Oct 20, 2026

Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.

An interventional study of Neptune and Standard clinical care in Parkinson Disease, sponsored by Copenhagen University Hospital, Rigshospitalet. Active, not recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Screening

How we know

Updated Oct 20, 2026Now Active, not recruitingStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.

Planned enrollment
17th of 33
75 · median 75
Started
2024
with 5 others
No phase
23 of 50
9 open now
Primary completion
2026-11
later than 4 of 17 live
Registered
36th of 50
by date

Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 17th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2024, is one of 23 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 36th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Parkinson Disease with a site in Denmark, or all of them as a file.
02

Study summary

The overall aim of the trial is to compare the efficacy of using wearables and patient-reported outcome measures versus standard care in enhancing the timeliness of referrals to advanced monitoring of treatments for people with Parkinson's Disease.

Read the detailed description

The study is a multicentre, parallel group, randomized controlled trial, investigating the value of using wearable devices and electronic patient-reported outcome measurements to improve clinical decision-making related to people with Parkinson's Disease.

Data from a wearable device and a mobile app will be compared to current standard of care.

75 participants will be recruited from the uptake area of the Movement Disorder Clinics (MDC) at Rigshospitalet Glostrup (RHG) and 5 private practice neurologists in Denmark. They will equally be randomized to one of two groups: Intervention or Standard of Care.

Each participant will take part of the trial for 6 months, in which they will have 3 study visits:

  • Baseline
  • Clinical visits at month 3 and 6
  • Final visit after 6 months

They will be asked to wear the device for 6 months. We will then compare decisions made related to changes in medication and referrals to advanced treatment.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Wearable Devices
  • Objective measurements
  • Advanced treatment
  • Digital health
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Idiopathic Parkinson's Disease
  • Taking five or more doses of levodopa daily, or 4 doses levodopa and a COMT-inhibitor
  • Experiencing fluctuations in motor function with regards to OFF time and/or dyskinesia.
  • Able and motivated to utilize a digital product, either alone or assisted by a caregiver.

Exclusion criteria

Exclusion Criteria:

  • Consistent use of a wheelchair or walker which may interfere significantly with the remote monitoring of PD motor symptoms.
  • Lack of understanding and proficiency in the Danish language.
  • Inability to use wearable devices due to non-compliance, physical and/or skin sensitivity.
  • Suffering from severe psychiatric disorders.
  • Otherwise not qualified to receive advanced treatment (e.g., advanced cancer, severe heart failure).
  • Already undergoing advanced treatment.
  • Diagnosed with atypical or secondary parkinsonism.
  • Other patient groups otherwise deemed ineligible by the project manager.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Intervention

    The intervention consists of a wrist-worn wearable sensor that tracks motor symptoms and an app for patient-reported outcomes.

    Device: Neptune

  • Active comparator
    Standard of Care

    The control group will wear the wrist-worn wearable sensor, but not be able to view the tracked data.

    Other: Standard clinical care

Interventions

  • DeviceNeptune

    Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can view their motor data, and a physician portal, where the treating physician can view the objective motor data prior to a clinical visit.

    Also known as: Neptune Care

  • OtherStandard clinical care

    Treatment and management according to standard clinical care

06

What researchers measure

Primary outcomes

  1. Differences between groups in proportion of patients referred to evaluation for advanced treatment.

    Differences in number of referrals based on access to digital measurements

    Time frame: 6 months

Secondary outcomes

  1. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Global Sleep Assessment Scale (GSAQ). Every question is scored from 0-3 (highest worst)

    Time frame: 6 months

  2. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Non-Motor Symptom Scale (NMSS). Scored from 0-360 (highest worst)

    Time frame: 6 months

  3. Changes in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale)

    Levodopa Equivalent Dose, LED, by use of Tomlinson's scale.

    Time frame: 6 months

  4. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scored from 0-52 (UPDRS-II), 0-132 (UPDRS-III) and 0-44 (UPDRS-IV) (highest worst)

    Time frame: 6 months

  5. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Parkinson's Disease Questionnaire (PDQ-39). Scored from 0-100 (highest worst)

    Time frame: 6 months

  6. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    EuroQol Questionnaire (EQ5D-5L). Scored from 0-1 and 0-100 (highest best).

    Time frame: 6 months

  7. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Patient Global Impressions Scale - Improvement score (measurements of QoL) (PGI-I). Every question is scored from 1-7 (highest worst)

    Time frame: 6 months

  8. System Usability Scale

    The System Usability Scale (SUS) is a simple, ten-statement questionnaire used to evaluate the usability of a system or product. It is scored from 0-100.

    Time frame: Completed at last visit of the study

  9. Referrals

    Clinician confidence in referral decision (5-point Likert scale) and reasons for referral

    Time frame: 6 months

  10. Medication adjustment

    Clinician confidence in changes in oral medication based on wearable data

    Time frame: 6 months

  11. Symptom burden

    Differences in wearable-based symptom burden (OFF/DYS vs ON time) between groups at the time of referral.

    Time frame: 6 months

  12. Referral time

    Differences between groups in time from inclusion to referral

    Time frame: 6 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Study data will be published in anonymized format as supplementary material to publications. Study protocol, SAP, ICF and analytic code will be available upon request.

Supporting information: Study protocol

Time frame: Data will be published as supplementary material to publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Oct 2024 → Nov 2024, primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 29, 2024
StartActual
Nov 1, 2024was Oct 2024
Primary completionEst.
Nov 1, 2026was Oct 2026
CompletionEst.
Nov 1, 2026was Oct 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Rigshospitalet Glostrup · Glostrup Municipality, Denmark
Show 1 removed
  • Rigshospitalet Glostrup · Glostrup, Denmark
Oct 20, 2026
Start date
Oct 1, 2024→Nov 1, 2024 (actual)
Oct 20, 2026
Primary completion
Oct 1, 2026→Nov 1, 2026
Oct 20, 2026
Study completion
Oct 1, 2026→Nov 1, 2026
Oct 20, 2026
Enrollment
90→75
Oct 20, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedTaking five or more doses of levodopa daily, or 4 doses levodopa and a COMT-inhibitor
  • EditedAble and motivated to utilize a digital product, either alone or assisted by a caregiver.
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Differences between groups in algorithm-based motor symptom burden (time spent in the ON state without dyskinesias) at referral to evaluation for advanced treatment.Now Differences between groups in proportion of patients referred to evaluation for advanced treatment.Time frame: 1 year → 6 months
Oct 20, 2026
Secondary outcomes
7 time frame changed, 5 added
What changed in the outcomes
  • AddedSystem Usability ScaleTime frame: Completed at last visit of the study
  • AddedReferralsTime frame: 6 months
  • AddedMedication adjustmentTime frame: 6 months
  • AddedSymptom burdenTime frame: 6 months
  • AddedReferral timeTime frame: 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.1 year → 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#21 year → 6 months
  • Time frameChanges in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale)1 year → 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#31 year → 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#41 year → 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#51 year → 6 months
  • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#61 year → 6 months
Oct 20, 2026
Sponsor
Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Rigshospitalet Glostrup · Glostrup Municipality, Denmark
    Show 1 removed
    • Rigshospitalet Glostrup · Glostrup, Denmark
    Start date Oct 1, 2024→Nov 1, 2024 (now actual)
    Primary completion Oct 1, 2026→Nov 1, 2026
    Study completion Oct 1, 2026→Nov 1, 2026
    Enrollment 90→75
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedTaking five or more doses of levodopa daily, or 4 doses levodopa and a COMT-inhibitor
    • EditedAble and motivated to utilize a digital product, either alone or assisted by a caregiver.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Differences between groups in algorithm-based motor symptom burden (time spent in the ON state without dyskinesias) at referral to evaluation for advanced treatment.Now Differences between groups in proportion of patients referred to evaluation for advanced treatment.Time frame: 1 year → 6 months
    Secondary outcomes 7 time frame changed, 5 added
    What changed in the outcomes
    • AddedSystem Usability ScaleTime frame: Completed at last visit of the study
    • AddedReferralsTime frame: 6 months
    • AddedMedication adjustmentTime frame: 6 months
    • AddedSymptom burdenTime frame: 6 months
    • AddedReferral timeTime frame: 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.1 year → 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#21 year → 6 months
    • Time frameChanges in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale)1 year → 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#31 year → 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#41 year → 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#51 year → 6 months
    • Time frameDifferences in questionnaire data from baseline (inclusion visit) to end-of-intervention.#61 year → 6 months
    Sponsor Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
    + 7 other changes: identifiers, verification date, description, design details, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06284629
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Bo Biering-Soerensen (MD, MPG, associate professor, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Feb 29, 2024
Start date
Nov 1, 2024
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

Bo Biering-Soerensen, MD
principal investigator · Copenhagen University Hospital, Rigshospitalet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion